ZEVRA THERAPEUTICS, INC.
ZVRANasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annualNo structured XBRL financials available (common for pre-2009 filers, foreign issuers, or companies that never reported as a US public company).
Signs
● 1 severe● 0 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 16, 2017
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Fmr LlcPassive (13G)May 6, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Woodline Partners LpPassive (13G)Nov 14, 2025
- Adage Capital Management, L.P.Passive (13G)Nov 13, 2025
- Nantahala Capital Management, LlcPassive (13G)Feb 14, 2025
- Blackrock, Inc.Passive (13G)Feb 5, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Thompson RahsaanOfficer — Chief Legal & Compliance | May 11, 2026 | Sell | 1,794 | $11.30 |
| Bode John BDirector | Mar 24, 2026 | Option exercise | 39,200 | $4.97 |
| Mcfarlane Neil F.Officer — President and CEO | Feb 7, 2026 | Option exercise | 37,500 | — |
| Sangiovanni Timothy J.Officer — SVP, Finance & Corp Controller | Feb 3, 2026 | Sell | 3,000 | $9.18 |
| Schafer JoshuaOfficer — CCO | Feb 3, 2026 | Sell | 10,500 | $9.19 |
| Sangiovanni Timothy J.Officer — SVP, Finance & Corp Controller | Jan 30, 2026 | Option exercise | 6,333 | — |
| Thompson RahsaanOfficer — Chief Legal & Compliance | Jan 30, 2026 | Option exercise | 11,333 | — |
| Quartel Adrian WOfficer — Chief Medical Officer | Jan 30, 2026 | Option exercise | 11,333 | — |
| Schafer JoshuaOfficer — CCO | Jan 30, 2026 | Option exercise | 11,333 | — |
| Mcfarlane Neil F.Officer — President and CEO | Jan 31, 2026 | Option exercise | 233,334 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 4.4M | 2.5 | -10.8% |
| Apr 30, 2026 | 5.0M | 6.1 | +4.3% |
| Apr 15, 2026 | 4.8M | 7.2 | +7.6% |
| Mar 31, 2026 | 4.4M | 4.8 | -6.0% |
| Mar 13, 2026 | 4.7M | 2.2 | -12.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 6, 2026
- Entered a material agreement · Terminated a material agreement · Regulation FD disclosureMar 16, 2026
- Results of operations · Director / officer changeMar 9, 2026
- Director / officer changeDec 17, 2025
- Director / officer change · Regulation FD disclosureDec 2, 2025
- Director / officer change · Regulation FD disclosureNov 20, 2025
- Results of operationsNov 5, 2025
- Results of operationsAug 12, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.